News and FDA Updates for Cortex (NYSE:COR), Elan (NYSE:ELN), Exelixis (NASDAQ:EXEL)

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com

On 12/09/09, Cortex Pharmaceuticals, Inc. (NYSE:COR) announced it has received notification from the NYSE Amex LLC indicating, due to the Company´s non-compliance with certain continued listing standards as previously reported, the Exchange intends to delist the Company´s common stock from the NYSE Amex effective as of the close of business on Friday, December 11, 2009.

On 12/09/09, Elan Corporation, plc (NYSE:ELN) announced it will present at the Deutsche Bank Securities Biotech Boston Confab Conference, on Tuesday, December 15, 2009, at 10:30 a.m. Eastern Time and 3:30 p.m. GMT.

On 12/09/09, Exelixis, Inc. (NASDAQ:EXEL) announced George A. Scangos, PhD, the company´s president and chief executive officer, will present at the 28th Annual J.P. Morgan Healthcare Conference at 11:00 a.m. EST / 8:00 a.m. PST on Tuesday January 12, 2010 in San Francisco.

Biotech investors interested in seeing more details about these stories and accessing the complete database of clinical trials and upcoming FDA decisions can access that information here:

http://biomedreports.com/fda-calendar/fda-calendar.html

Disclosure: No positions.

About BiomedReports.Com

BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.

For more biomedical sector and investment news, go to www.BioMedReports.com

Certain sections of this report contain forward-looking statements that are based on our reporters´ expectations, estimates, projections and assumptions. Words such as "expects" "anticipates" "plans" "believes" "scheduled" "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company´s behalf are qualified by the cautionary statements in this section. BioMedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.